Indinavir: A Comprehensive Overview Of A Pioneering HIV Protease Inhibitor
Indinavir is a synthetic antiretroviral drug belonging to the class of protease inhibitors (PIs), first approved by the U.S. Food and Drug Administration (FDA) in 1996 for the treatment of human immunodeficiency virus (HIV) infection. As one of the earliest PIs introduced into clinical practice, Indinavir played a pivotal role in transforming HIV from a near-certain fatal illness into a manageable chronic condition, particularly when used as part of highly active antiretroviral therapy (HAART). This report provides a concise yet thorough review of Indinavir, covering its chemical properties, mechanism of action, pharmacological profile, clinical efficacy, adverse effects, resistance patterns, and current status in HIV therapy.
Chemically, Indinavir sulfate is a white to off-white powder with a molecular formula of C36H47N5O4·H2SO4 and a molecular weight of approximately 711.88 g/mol. It is a hydroxyethylamine derivative designed to mimic the natural substrate of HIV-1 protease. The drug is administered orally, typically in capsule form, with the standard dose being 800 mg every 8 hours (three times daily) when used as a component of a combination regimen. However, due to its complex pharmacokinetics and significant food interactions—absorption is markedly reduced by a high-fat meal—Indinavir is recommended to be taken on an empty stomach or with a light, low-fat meal. The drug is extensively metabolized in the liver via cytochrome P450 3A4 (CYP3A4), and it also acts as both a substrate and an inhibitor of this enzyme, leading to numerous drug-drug interactions.
The mechanism of action of Indinavir is typical of HIV protease inhibitors. HIV-1 protease is a viral enzyme essential for the cleavage of the Gag-Pol polyprotein into functional proteins, a late step in the viral replication cycle. Indinavir binds competitively and reversibly to the active site of the protease, thereby preventing the processing of viral precursor proteins into mature, infectious virions. This results in the production of non-infectious viral particles, effectively halting the spread of HIV to uninfected cells. When used in combination with two nucleoside reverse transcriptase inhibitors (NRTIs), Indinavir durably suppresses plasma HIV RNA levels, increases CD4+ T cell counts, and reduces morbidity and mortality.
Clinical efficacy of Indinavir was established in landmark trials such as the AIDS Clinical Trials Group (ACTG) 320 study, which demonstrated that adding Indinavir to a background of zidovudine and lamivudine significantly reduced progression to AIDS and death compared to dual NRTI therapy alone. Long-term follow-up confirmed that viral suppression achieved with Indinavir-containing HAART could be sustained for years, although adherence was challenging due to the thrice-daily dosing schedule and the requirement for an empty stomach. Indinavir was also one of the first PIs used in post-exposure prophylaxis and in salvage therapy for patients with resistance to other agents.
Despite its initial success, Indinavir is associated with a substantial side effect profile that limits its use in modern practice. The most well-known adverse effect is nephrolithiasis (kidney stones), which occurs in approximately 10–20% of patients and is caused by the poor aqueous solubility of Indinavir, leading to crystal precipitation in the renal tubules. This can manifest as flank pain, hematuria, and dysuria, and requires hydration and sometimes dose interruption or change of therapy. Other common adverse effects include gastrointestinal disturbances (nausea, vomiting, diarrhea), hyperbilirubinemia (often asymptomatic due to inhibition of UDP-glucuronosyltransferase), lipodystrophy (fat redistribution), insulin resistance and hyperglycemia, dyslipidemia (elevated triglycerides and cholesterol), and hepatotoxicity. Additionally, Indinavir can cause a characteristic "more than moderate" increase in serum transaminases. Because of its metabolic effects, it has been associated with an increased risk of cardiovascular events in some studies, ; https://ballyes.es/images/products/seroquel.webp, although the causal link is confounded by underlying HIV and other risk factors.
Resistance to Indinavir develops through mutations in the HIV-1 protease gene, particularly at positions 46, 82, 84, and 90, among others. Cross-resistance with other PIs is common; for example, the mutation V82A confers resistance to Indinavir and also to ritonavir and amprenavir, although susceptibility to other agents like darunavir may be retained. The genetic barrier to resistance for Indinavir is considered moderate—lower than that of boosted PIs like lopinavir/ritonavir or darunavir/ritonavir. To overcome pharmacokinetic limitations and reduce dosing frequency, Indinavir was sometimes co-administered with low-dose ritonavir (a potent CYP3A4 inhibitor) to boost its plasma levels, allowing twice-daily dosing. This regimen (Indinavir 800 mg plus ritonavir 100 mg every 12 hours) improved convenience but did not eliminate the risk of nephrolithiasis.
Today, the role of Indinavir in HIV therapy has waned considerably. It is no longer recommended as a first-line agent in most treatment guidelines, including those of the World Health Organization (WHO) and the U.S. Department of Health and Human Services (DHHS), due to the availability of better-tolerated, more convenient, and more robust PIs (e.g., darunavir boosted with ritonavir or cobicistat, atazanavir, etc.) as well as integrase strand transfer inhibitors (INSTIs) like dolutegravir. Indinavir is still available in some resource-limited settings but is largely considered obsolete in well-resourced countries. Its use is primarily restricted to salvage therapy when resistance limits options, and even then, newer agents are preferred. The drug has also been studied in experimental settings for conditions such as cervical cancer and SARS-CoV-2, but these uses remain off-label and unproven.
In summary, Indinavir was a groundbreaking drug that helped define the HAART era, demonstrating that HIV could be suppressed effectively for prolonged periods. Its mechanism as a protease inhibitor is well understood, and its clinical benefits were clear. However, its complex pharmacokinetics, inconvenient dosing, frequent adverse effects (especially kidney stones), and moderate resistance barrier have relegated it to a secondary or tertiary option in modern ARV formularies. Nonetheless, Indinavir remains an important part of antiretroviral history, exemplifying the challenges and triumphs of early HIV pharmacotherapy. For clinicians, it serves as a lesson in balancing efficacy, tolerability, and adherence—a balance that continues to evolve with the introduction of newer, simpler regimens.
